Literature DB >> 12670123

Exposure to increased pressure or hyperbaric oxygen suppresses interferon-gamma secretion in whole blood cultures of healthy humans.

E V Granowitz1, E J Skulsky, R M Benson, J Wright, J L Garb, E R Cohen, E C Smithline, R B Brown.   

Abstract

This study examines the effects of hyperoxia, increased atmospheric pressure, and hyperbaric oxygen on cytokine synthesis. Five healthy volunteers were exposed to 90 min of room air, 100% oxygen, 10.5% oxygen at 2 atm abs, or 100% oxygen at 2 atm abs (HBO2). All subjects were blinded and randomly exposed to each of the 4 conditions. Immediately before entering the chamber, immediately after exposure, and 3 and 24 h later, blood was drawn and stimulated ex vivo with phorbol myristate acetate (PMA) and phytohemagglutinin A (PHA). Since lymphocytes are the primary source of PMA/PHA-induced interferon-gamma (IFN-gamma), these results were expressed as IFN-gamma production per 10(6) lymphocytes. Following the HBO2 exposure, PMA/PHA-stimulated lymphocytes released 51% less IFN-gamma than cells obtained before the exposure. This suppression persisted for 24 h following HBO2 (P < 0.05). Surprisingly, increased atmospheric pressure alone also inhibited IFN-gamma secretion (P < 0.05). Room air and hyperoxia alone had no significant effect upon IFN-gamma release. HBO2's anti-inflammatory effect may, in part, be due to inhibition of IFN-gamma release.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12670123

Source DB:  PubMed          Journal:  Undersea Hyperb Med        ISSN: 1066-2936            Impact factor:   0.698


  13 in total

1.  Hyperbaric oxygen therapy and liver transplantation.

Authors:  Vijayaragavan Muralidharan; Chris Christophi
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

2.  The relationship between N-acetylcysteine, hyperbaric oxygen, and inflammation in a rat model of acetaminophen-induced nephrotoxicity.

Authors:  Hakan Cermik; Mine Yavuz Taslipinar; Ibrahim Aydin; Mehmet Agilli; Fevzi Nuri Aydin; Fatma Ucar; Bilal Firat Alp; Mehmet Toygar; Esin Ozkan; Ertan Altayli; Tuncer Cayci
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

Review 3.  Hyperbaric oxygen therapy for malignancy: a review.

Authors:  Jurstine Daruwalla; Chris Christophi
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

4.  The role of hyperbaric oxygen therapy in the treatment of radiation lesions.

Authors:  Clara Gaio-Lima; João Castedo; Mafalda Cruz; Margarida Candeias; Óscar Camacho
Journal:  Clin Transl Oncol       Date:  2022-08-17       Impact factor: 3.340

5.  Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages.

Authors:  R M Benson; L M Minter; B A Osborne; E V Granowitz
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 6.  Old but new methods in radiation oncology: hyperbaric oxygen therapy.

Authors:  Kazuhiko Ogawa; Kiyotaka Kohshi; Syogo Ishiuchi; Masayuki Matsushita; Naoki Yoshimi; Sadayuki Murayama
Journal:  Int J Clin Oncol       Date:  2013-03-05       Impact factor: 3.402

7.  Hyperbaric oxygen treatment in autism spectrum disorders.

Authors:  Daniel A Rossignol; James J Bradstreet; Kyle Van Dyke; Cindy Schneider; Stuart H Freedenfeld; Nancy O'Hara; Stephanie Cave; Julie A Buckley; Elizabeth A Mumper; Richard E Frye
Journal:  Med Gas Res       Date:  2012-06-15

8.  Hyperbaric oxygen therapy as a sole agent is not immunosuppressant in a highly immunogenic mouse model.

Authors:  Adam Gassas; Weixian Min; A Wayne Evans; Susan Carter; George K Sándor; Eyal Grunebaum
Journal:  Bone Marrow Res       Date:  2010-08-03

9.  Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis.

Authors:  Daniel A Rossignol
Journal:  Med Gas Res       Date:  2012-03-15

10.  Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial.

Authors:  Daniel A Rossignol; Lanier W Rossignol; Scott Smith; Cindy Schneider; Sally Logerquist; Anju Usman; Jim Neubrander; Eric M Madren; Gregg Hintz; Barry Grushkin; Elizabeth A Mumper
Journal:  BMC Pediatr       Date:  2009-03-13       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.